Abstract:<a href="/products/ejournals/abstract/10.1055/a-0914-0535">Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation</a>Dear Editor,We wish to share our concern with significant aspects of the scientific design, analysis, and validity of the work "Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation" by S. Allelein, T. Diana, M. Ehlers, M. Kanitz, D. Hermsen, M. Schott, and G. J. Kahaly [<a href="#R2019-09-0291-0001">1</a>], which affect the reliability of the authors' conclusions. In this publication, the authors sought to compare the FDA-cleared IMMULITE® 2000/2000 XPi TSI immunoassay with the FDA-cleared ThyretainTM TSI Reporter BioAssay and the non-FDA-cleared Thyretain TBI Blocking Reporter BioAssay on a set of patients, including those diagnosed with Graves' disease (GD) and Hashimoto's thyroiditis (HT). The authors purport to determine the presence of blocking antibodies using the non-FDA-cleared Thyretain TBI bioassay. The authors find that "[b]oth assays were highly sensitive for detecting TSHR-Ab in hyperthyroid patients with untreated GD". Both TSI assays were positive for all ten untreated GD patients. The authors also found that both TSI assays correctly report negative results in all healthy patients. The clinical specificity of the two TSI assays was evaluated using 78 patients with HT, non-autoimmune nodular thyroid disease, and thyroid cancer. The IMMULITE TSI assay demonstrated a clinical specificity of 97.4% (76/78) compared to 93.6% (73/78) for the Thyretain TSI assay. These findings agree with previous third-party evaluations of the IMMULITE TSI assay showing 98–100% clinical sensitivity and 98.2–99.9% clinical specificity for the differential diagnosis of GD [<a href="#R2019-09-0291-0002">2</a>][<a href="#R2019-09-0291-0003">3</a>][<a href="#R2019-09-0291-0004">4</a>][<a href="#R2019-09-0291-0005">5</a>][<a href="#R2019-09-0291-0006">6</a>].However, the authors suggest that since two treated Graves' disease patients were negative in the Thyretain TSI assay but positive in both the IMMULITE TSI assay and the non-FDA-cleared Thyretain TBI bioassay, the IMMULITE TSI assay can be described as not specific for TSH receptor stimulating autoantibodies. The authors' interpretation of the Thyretain TSI assay results is incorrect because of the experimental design flaws and incomplete analysis of the data. A plausible explanation of the data is that the Thyretain TSI assay results for the two treated GD patients are false negative, and the IMMULITE TSI assay results are true positive.First, the authors do not mention the explicit warning against the use of the Thyretain TSI assay to test GD patients undergoing various drug treatments. The Thyretain TSI Reporter BioAssay package insert [<a href="#R2019-09-0291-0007">7</a>] unambiguously states that "[t]he TSI Reporter assay is intended for the qualitative detection of TSI. It is not intended for use in monitoring a patient's treatment. The effects of various drug therapies on the performance of this Kit have not been established" [<a href="#R2019-09-0291-0007">7</a>]. Therefore, the validity of the negative Thyretain TSI results for the two treated GD patients is in question.Second, the Thyretain TSI Reporter BioAssay manufacturer also clearly states in the package insert that "[a] negative result does not exclude the possibility of the presence of TSI. Results of the test should be interpreted in conjunction with information available from other clinical information, such as physical symptoms and thyroid hormone testing, as recommended by the American Thyroid Association (ATA)" [<a href="#R2019-09-0291-0007">7</a>]. Thus, the authors' claim that there are no stimulating antibodies in the samples of the two treated GD patients is unfounded because it is based on negative Thyretain TSI results and ignores the manufacturer's recommendation based on ATA guidelines to interpret the test result in conjunction with other clinical information.Third, the authors fail to mention or consider in their analysis that the Thyretain TSI assay reports net stimulating activity as documented in previous publications by some of the authors of this study [<a href="#R2019-09-0291-0008">8</a>][<a href="#R2019-09-0291-0009">9</a>]. Although blocking antibodies do not generate a signal in the Thyretain TSI assay, blocking antibodies, when present, interfere with that assay's measurement of stimulating antibodies [<a href="#R2019-09-0291-0008">8</a>][<a href="#R2019-09-0291-0009">9</a>]. As such, the assay reports "zero" net stimulating activity for samples containing equal activity of stimulating and blocking antibodies. For example, a 2017 article by Diana et al. showed that a sample with 4 ng/ml stimulati -Abstract Truncated-

Misdiagnosis of Graves' hyperthyroidism due to therapeutic biotin intervention

How Biotin Induces Misleading Results in Thyroid Bioassays: Case Series

Abstract 120: Effect of biotin on thyroid function test

MON-475 Discrepant Thyroid Function Tests in Adenocarcinoma-Is This a True Thyroid Disorder?

Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm

Effect of biotin on currently used Beckman thyroglobulin assay and newly reformulated thyroglobulin assay not affected by biotin

False Laboratory Thyroid Function Tests after Biotin Treatment in a Neonate with Shock and Suspect of Metabolic Disorder

Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave's disease: a Belgian case report

Falsely elevated T 3 due to interference of anti-T 3 autoantibodies: a case report

Biotin as a masking agent in chorionic gonadotropin assays utilizing biotinylated antibodies

[Hard Nut to Crack in Diagnosis of Pituitary Hyperplasia Secondary to Primary Hypothyroidism and Reasons of Misdiagnosis].

A Negative Thyretain TSI Bioassay Result does not Exclude the Possibility of the Presence of TSI

DIAGNOSIS OF ENDOCRINE DISEASE: How reliable are free thyroid and total T3 hormone assays?

Clinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves' orbitopathy patients: a comparison with two commonly used immunoassays

Discordant TFT in Lupus Nephritis Patients: A Case Report and Comprehensive Literature Review

US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease

False diagnosis of recurrent thyroid carcinoma: the importance of testing for heterophile antibodies

Impact of Biotin Supplementation on Human Chorionic Gonadotropin Immunoassays Utilizing Biotin-Streptavidin Binding Methods in Urine

Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

Effects of Thyrotropin on Peripheral Thyroid Hormone Metabolism and Serum Lipids